On May 13, Jimin Pharmaceutical (603222) recently announced that Zhang Xueqin, the shareholder of the company, reduced 3.1999 million shares of the company by means of centralized bidding transaction. The price range of this reduction is 13.88-18.90 yuan / share, and the cash out is 58.1397 million yuan.
According to the announcement, Zhang Xueqin held 39069200 shares of the company before the reduction, and 35869300 shares after the reduction, accounting for 10.53% of the total share capital.
According to the company’s report for the first quarter of 2021, the company’s net profit attributable to shareholders of Listed Companies in the first quarter of 2021 was 39943254.67 yuan, turning losses into profits over the same period of last year.
According to the data of digbei.com, Jimin pharmaceutical’s main business includes three business segments: R & D, production and sales of medical devices, medical service, and R & D, production and sales of infusion products.